uric acid has been researched along with Diabetic Nephropathies in 174 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia." | 9.34 | Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. ( Liu, J; Sun, X; Wang, G, 2020) |
| " A total of 65 patients with hyperuricemia and diabetic nephropathy with microalbuminuria were enrolled and assigned to either the topiroxostat group or the placebo group." | 9.27 | Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study). ( Honda, D; Hosoya, T; Kimura, K; Narita, K; Okui, D; Sakamoto, R; Sasaki, T; Wada, T, 2018) |
| "Previous studies have discussed the relationship between simple renal cysts (SRC) and serum uric acid level in healthy individuals." | 9.24 | Hyperuricemia and overexcretion of uric acid increase the risk of simple renal cysts in type 2 diabetes. ( Bao, Y; Chen, H; Han, J; Han, Y; Jia, W; Lu, J; Zhang, L; Zhang, M; Zhao, F, 2017) |
| "To investigate the effect of levothyroxine (LT4) therapy on urinary albumin excretion rate (UAER) in early type 2 diabetic nephropathy (DN) and subclinical hypothyroidism (SCH) patients with mildly increased thyroid stimulating hormone (TSH) levels and serum thyroid peroxidase antibody (TPO-Ab) positivity." | 9.20 | Can levothyroxine treatment reduce urinary albumin excretion rate in patients with early type 2 diabetic nephropathy and subclinical hypothyroidism? A randomized double-blind and placebo-controlled study. ( Chen, X; Chen, Y; Liu, P; Liu, R; Wang, D; Wang, Y; Zhang, F, 2015) |
| " Nevertheless, the association between uric acid levels and the development of albuminuria has been under-investigated in patients with type 2 diabetes mellitus." | 8.02 | Association between uric acid level and incidence of albuminuria in patients with type 2 diabetes mellitus: A 4.5-year cohort study. ( Chen, LJ; Chen, YY; Ku, PW; Lai, YJ; Yen, YF, 2021) |
| "To analyze the associations of serum uric acid (SUA) level with diabetic microvascular complications, including diabetic retinopathy (DR) and diabetic nephropathy (DN), in patients with type 2 diabetes mellitus (DM)." | 7.96 | Associations of serum uric acid level with diabetic retinopathy and albuminuria in patients with type 2 diabetes mellitus. ( Chen, Q; Hou, L; Li, Q; Shi, Y; Wang, S; Zhao, M; Zhou, X, 2020) |
| "This study aims to investigate the relationship between serum uric acid (SUA) and the severity of diabetic nephropathy (DN) and diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM)." | 7.96 | Serum uric acid is independently associated with diabetic nephropathy but not diabetic retinopathy in patients with type 2 diabetes mellitus. ( Hu, AP; Li, DM; Su, S; Xia, Q; Yang, SM; Zhang, SH; Zhu, J; Zhu, XL, 2020) |
| "Although the relation between serum uric acid (SUA) and left ventricular hypertrophy (LVH) has been studied for decades, however, their association remains debatable." | 7.85 | Increased Serum Uric Acid Level Is a Risk Factor for Left Ventricular Hypertrophy but Not Independent of eGFR in Patients with Type 2 Diabetic Kidney Disease. ( Bao, H; Chen, Y; Cheng, D; Fan, Y; Jian, G; Li, J; Sheng, X; Wang, N; Zeng, C, 2017) |
| "To assess the prospective association between baseline serum uric acid level and subsequent risk of development or progression in albuminuria." | 7.83 | Association of serum uric acid levels with the risk of development or progression of albuminuria among Japanese patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 10)]. ( Hayashino, Y; Ishii, H; Okamura, S; Tsujii, S, 2016) |
| "This is the first large study showing that serum uric acid is not associated with an increase in the risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary revascularization." | 7.80 | Uric acid and risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention. ( Barbieri, L; De Luca, G; Di Giovine, G; Marino, P; Schaffer, A; Verdoia, M, 2014) |
| "Serum uric acid (SUA) has been suggested as a potentially modifiable mediator associated with the metabolic syndrome." | 7.80 | Serum uric acid, the metabolic syndrome, and the risk of chronic kidney disease in patients with type 2 diabetes. ( Esteghamati, A; Fotouhi, A; Hafezi-Nejad, N; Nakhjavani, M; Sheikhbahaei, S, 2014) |
| "Serum uric acid is a predictor of cardiac events and correlates to N-terminal pro-B-type natriuretic peptide and albuminuria, underscoring the importance of uric acid as a cardiovascular risk marker in patients with diabetes." | 7.78 | Serum uric acid is related to cardiovascular events and correlates with N-terminal pro-B-type natriuretic peptide and albuminuria in patients with diabetes mellitus. ( Clodi, M; Hülsmann, M; Kromoser, H; Luger, A; Neuhold, S; Pacher, R; Prager, R; Resl, M; Riedl, M; Strunk, G; Vila, G, 2012) |
| "The following factors were selected in the stepwise multivariate model as predictors of micro- or macroalbuminuria at the 6-year follow-up visit: baseline serum uric acid levels, HbA(1c) and pre-albuminuria." | 7.76 | Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. ( Jalal, DI; Johnson, RJ; Maahs, DM; McFann, K; Rewers, M; Rivard, CJ; Snell-Bergeon, JK, 2010) |
| " The aim of this study was to evaluate the relationships between serum uric acid concentration and degree of urinary albumin excretion as well as markers of subclinical atherosclerosis in men with type 2 diabetes mellitus." | 7.74 | Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus. ( Asano, M; Fukui, M; Harusato, I; Hasegawa, G; Hosoda, H; Kadono, M; Nakamura, N; Shiraishi, E; Tanaka, M; Yoshikawa, T, 2008) |
| "To assess the impacts of insulin resistance and renal function on plasma total homocysteine (tHcy) levels in patients with type 2 diabetes with a wide range of nephropathy." | 7.71 | Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. ( Emoto, M; Inaba, M; Ishimura, E; Kanda, H; Kawagishi, T; Komatsu, M; Mori, K; Nishizawa, Y; Okuno, Y; Shoji, T; Tahara, H, 2001) |
| "The relationship between elevated serum uric acid (SUA) and coronary heart disease (CHD) is discussed controversially." | 7.68 | Association of elevated serum uric acid with coronary heart disease in diabetes mellitus. ( Dannehl, K; Gries, FA; Hauner, H; Rathmann, W, 1993) |
| "Hyperuricemia was common in youth with T2D." | 5.51 | Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An Observational Analysis From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Stu ( Bjornstad, P; El Ghormli, L; Laffel, L; Lynch, J; Nadeau, KJ; Tollefsen, SE; Weinstock, RS, 2019) |
| "Early detection diabetic nephropathy (DN) is important." | 5.43 | Serum uric acid and its association with hypertension, early nephropathy and chronic kidney disease in type 2 diabetic patients. ( Fathy, H; Fouad, M; Zidan, A, 2016) |
| "This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia." | 5.34 | Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. ( Liu, J; Sun, X; Wang, G, 2020) |
| " A total of 65 patients with hyperuricemia and diabetic nephropathy with microalbuminuria were enrolled and assigned to either the topiroxostat group or the placebo group." | 5.27 | Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study). ( Honda, D; Hosoya, T; Kimura, K; Narita, K; Okui, D; Sakamoto, R; Sasaki, T; Wada, T, 2018) |
| "Previous studies have discussed the relationship between simple renal cysts (SRC) and serum uric acid level in healthy individuals." | 5.24 | Hyperuricemia and overexcretion of uric acid increase the risk of simple renal cysts in type 2 diabetes. ( Bao, Y; Chen, H; Han, J; Han, Y; Jia, W; Lu, J; Zhang, L; Zhang, M; Zhao, F, 2017) |
| " The secondary outcome was the change in albuminuria and serum uric acid (UA)." | 5.22 | The Effect of Allopurinol on Renal Outcomes in Patients with Diabetic Kidney Disease: A Systematic Review and Meta-Analysis. ( Chen, L; Duan, Q; He, D; Wu, B; Xu, Y; Zheng, Z, 2022) |
| "To investigate the effect of levothyroxine (LT4) therapy on urinary albumin excretion rate (UAER) in early type 2 diabetic nephropathy (DN) and subclinical hypothyroidism (SCH) patients with mildly increased thyroid stimulating hormone (TSH) levels and serum thyroid peroxidase antibody (TPO-Ab) positivity." | 5.20 | Can levothyroxine treatment reduce urinary albumin excretion rate in patients with early type 2 diabetic nephropathy and subclinical hypothyroidism? A randomized double-blind and placebo-controlled study. ( Chen, X; Chen, Y; Liu, P; Liu, R; Wang, D; Wang, Y; Zhang, F, 2015) |
| "Type 2 diabetes is associated with excessively low urine pH, which increases the risk for uric acid nephrolithiasis." | 5.14 | Metabolic basis for low urine pH in type 2 diabetes. ( Cameron, MA; Maalouf, NM; Moe, OW; Sakhaee, K, 2010) |
| " High-serum uric acid can trigger renal inflammation." | 5.12 | The roles of NLRP3 inflammasome-mediated signaling pathways in hyperuricemic nephropathy. ( Fu, P; Ma, L; Wen, L; Yang, H, 2021) |
| "The objectives of this study were to compare the effects of the angiotensin II receptor blocker, losartan, to those of the angiotensin-converting enzyme inhibitor, enalapril, on albuminuria and renal function in relationship to clinic and ambulatory blood pressure (ABP) in hypertensive type 2 diabetic subjects with early nephropathy." | 5.09 | Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. ( Bélanger, A; Godin, C; Hallé, JP; Lacourcière, Y; Marion, J; Ross, S; Wright, N, 2000) |
| "Previous studies suggested that increased serum uric acid (SUA) level is an independent risk factor for albuminuria in Type 2 diabetes (T2D) patients." | 4.12 | Elevated serum uric acid is not an independent risk factor for the occurrence of Type 2 diabetic kidney disease in Chinese populations. ( An, X; Sun, J; Tian, R; Wang, X; Yu, J; Zhou, Y; Zhu, L, 2022) |
| " Nevertheless, the association between uric acid levels and the development of albuminuria has been under-investigated in patients with type 2 diabetes mellitus." | 4.02 | Association between uric acid level and incidence of albuminuria in patients with type 2 diabetes mellitus: A 4.5-year cohort study. ( Chen, LJ; Chen, YY; Ku, PW; Lai, YJ; Yen, YF, 2021) |
| "To analyze the associations of serum uric acid (SUA) level with diabetic microvascular complications, including diabetic retinopathy (DR) and diabetic nephropathy (DN), in patients with type 2 diabetes mellitus (DM)." | 3.96 | Associations of serum uric acid level with diabetic retinopathy and albuminuria in patients with type 2 diabetes mellitus. ( Chen, Q; Hou, L; Li, Q; Shi, Y; Wang, S; Zhao, M; Zhou, X, 2020) |
| "This study aims to investigate the relationship between serum uric acid (SUA) and the severity of diabetic nephropathy (DN) and diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM)." | 3.96 | Serum uric acid is independently associated with diabetic nephropathy but not diabetic retinopathy in patients with type 2 diabetes mellitus. ( Hu, AP; Li, DM; Su, S; Xia, Q; Yang, SM; Zhang, SH; Zhu, J; Zhu, XL, 2020) |
| " This review discussed the non-glycemic effects of SGLT-2is in patients with T2D and renal impairment, including reductions in systolic and diastolic blood pressure, decreases in albuminuria and plasma uric acid, changes in estimated glomerular filtration rate, and minimal changes in electrolytes." | 3.91 | Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment. ( Weir, MR, 2019) |
| "In this study, we aimed to analyze the relationship between serum uric acid (UA) and microalbuminuria as a marker of renal injury in type 2 diabetes mellitus." | 3.91 | Is Uric Acid elevation a random finding or a causative agent of diabetic nephropathy? ( Aktas, G; Atak, BM; Duman, TT; Kocak, MZ; Savli, H, 2019) |
| "Although the relation between serum uric acid (SUA) and left ventricular hypertrophy (LVH) has been studied for decades, however, their association remains debatable." | 3.85 | Increased Serum Uric Acid Level Is a Risk Factor for Left Ventricular Hypertrophy but Not Independent of eGFR in Patients with Type 2 Diabetic Kidney Disease. ( Bao, H; Chen, Y; Cheng, D; Fan, Y; Jian, G; Li, J; Sheng, X; Wang, N; Zeng, C, 2017) |
| "To assess the prospective association between baseline serum uric acid level and subsequent risk of development or progression in albuminuria." | 3.83 | Association of serum uric acid levels with the risk of development or progression of albuminuria among Japanese patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 10)]. ( Hayashino, Y; Ishii, H; Okamura, S; Tsujii, S, 2016) |
| " There were positive correlations between NAFLD and insulin resistance index (HOMA-IR), free fatty acids (FFA), tumor necrosis factor-α (TNF-α), omentin-1, visceral fat area, homocysteine (HCY), and serum uric acid (UA)." | 3.81 | Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. ( Di, F; Gao, L; Jia, G; Li, N; Li, Q; Shao, J; Wang, L; Wang, Q, 2015) |
| " We investigated the role of soluble uric acid in NLRP3 inflammasome activation in macrophages to demonstrate the effect of systemic hyperuricemia on progressive kidney damage in type 2 diabetes." | 3.81 | Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy. ( Choi, YW; Ihm, CG; Jeong, KH; Kim, DJ; Kim, SM; Kim, SY; Kim, YG; Lee, SH; Lee, TW; Moon, JY; Seo, JW; Won, KY, 2015) |
| "This is the first large study showing that serum uric acid is not associated with an increase in the risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary revascularization." | 3.80 | Uric acid and risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention. ( Barbieri, L; De Luca, G; Di Giovine, G; Marino, P; Schaffer, A; Verdoia, M, 2014) |
| "Serum uric acid (SUA) has been suggested as a potentially modifiable mediator associated with the metabolic syndrome." | 3.80 | Serum uric acid, the metabolic syndrome, and the risk of chronic kidney disease in patients with type 2 diabetes. ( Esteghamati, A; Fotouhi, A; Hafezi-Nejad, N; Nakhjavani, M; Sheikhbahaei, S, 2014) |
| "In the univariate analysis, the major risk factors for kidney dysfunction in the patients with the cardio-cerebrovascular disease were age, gender, hypertension, diabetes mellitus, dyslipidemia and serum uric acid." | 3.80 | High prevalence and risk factors for kidney dysfunction in patients with atherosclerotic cardio-cerebrovascular disease. ( Bao, YS; Ji, Y; Jia, XB; Na, SP; Yang, J; Zhao, SL, 2014) |
| " We calculated the mean values for proteinuria and serum phosphate, calcium, uric acid, and PTH, as well as 24-hour urinary excretion of urea nitrogen over time for each patient." | 3.79 | Factors related with the progression of chronic kidney disease. ( Abad, S; Ampuero, J; Aragoncillo-Sauco, I; Barraca, D; López-Gómez, JM; Ruiz-Caro, C; Vega-Martínez, A; Verdalles-Guzmán, Ú; Yuste, C, 2013) |
| "Serum uric acid is a predictor of cardiac events and correlates to N-terminal pro-B-type natriuretic peptide and albuminuria, underscoring the importance of uric acid as a cardiovascular risk marker in patients with diabetes." | 3.78 | Serum uric acid is related to cardiovascular events and correlates with N-terminal pro-B-type natriuretic peptide and albuminuria in patients with diabetes mellitus. ( Clodi, M; Hülsmann, M; Kromoser, H; Luger, A; Neuhold, S; Pacher, R; Prager, R; Resl, M; Riedl, M; Strunk, G; Vila, G, 2012) |
| " The following parameters discriminated progressors from non-progressors by univariate analysis: baseline-blood pressure (BP) parameters, eGFR and proteinuria as well as serum uric acid." | 3.78 | A study of the natural history of diabetic kidney disease (DKD). ( Altemtam, N; El Nahas, M; Russell, J, 2012) |
| "The following factors were selected in the stepwise multivariate model as predictors of micro- or macroalbuminuria at the 6-year follow-up visit: baseline serum uric acid levels, HbA(1c) and pre-albuminuria." | 3.76 | Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. ( Jalal, DI; Johnson, RJ; Maahs, DM; McFann, K; Rewers, M; Rivard, CJ; Snell-Bergeon, JK, 2010) |
| " The aim of this study was to evaluate the relationships between serum uric acid concentration and degree of urinary albumin excretion as well as markers of subclinical atherosclerosis in men with type 2 diabetes mellitus." | 3.74 | Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus. ( Asano, M; Fukui, M; Harusato, I; Hasegawa, G; Hosoda, H; Kadono, M; Nakamura, N; Shiraishi, E; Tanaka, M; Yoshikawa, T, 2008) |
| "The respective uric acid levels for normoalbuminuria (N= 166), microalbuminuria (N= 130), and macroalbuminuria (N= 47) were 5." | 3.73 | Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. ( Tseng, CH, 2005) |
| "To assess the impacts of insulin resistance and renal function on plasma total homocysteine (tHcy) levels in patients with type 2 diabetes with a wide range of nephropathy." | 3.71 | Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. ( Emoto, M; Inaba, M; Ishimura, E; Kanda, H; Kawagishi, T; Komatsu, M; Mori, K; Nishizawa, Y; Okuno, Y; Shoji, T; Tahara, H, 2001) |
| "The relationship between elevated serum uric acid (SUA) and coronary heart disease (CHD) is discussed controversially." | 3.68 | Association of elevated serum uric acid with coronary heart disease in diabetes mellitus. ( Dannehl, K; Gries, FA; Hauner, H; Rathmann, W, 1993) |
| " Examples of calculating the risk for gout attack and of EPH gestosis, depending on serum uric acid level, is presented." | 3.67 | [Criteria for the selection and evaluation of diagnostic tests]. ( Keller, H, 1985) |
| " The linear dose-response analysis revealed that the risk of DKD increased by 24% for each 1 mg/dl increase of SUA." | 2.82 | Serum uric acid levels and diabetic kidney disease in patients with type 2 diabetes mellitus: A dose-response meta-analysis. ( Feng, J; Ji, P; Li, H; Qin, H; Wei, L; Yu, Q; Zhang, J; Zhu, J, 2022) |
| "Patients with type 2 diabetes and UASF had lower 24-h urine pH than NV." | 2.72 | Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. ( Adams-Huet, B; Cameron, MA; Maalouf, NM; Moe, OW; Sakhaee, K, 2006) |
| "However, no study on diabetic nephropathy has been reported." | 2.71 | Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy. ( Akizawa, T; Koide, K; Koshikawa, S; Sanaka, T, 2004) |
| "Diabetic nephropathy is a long-standing microvascular complication of diabetes mellitus and is the leading cause of end stage renal disease in developed countries." | 2.52 | Uric acid as a biomarker and a therapeutic target in diabetes. ( Cherney, DZ; Lytvyn, Y; Perkins, BA, 2015) |
| "A major challenge in preventing diabetic nephropathy is the inability to identify high-risk patients at an early stage, emphasizing the importance of discovering new therapeutic targets and implementation of clinical trials to reduce diabetic nephropathy risk." | 2.50 | Early diabetic nephropathy in type 1 diabetes: new insights. ( Bjornstad, P; Cherney, D; Maahs, DM, 2014) |
| "Uric acid has been associated with renal disease, even though hyperuricemia may be a marker of or by itself be responsible for microvascular disease in diabetes." | 2.47 | Serum uric acid as a new player in the development of diabetic nephropathy. ( Hovind, P; Johnson, RJ; Parving, HH; Rossing, P, 2011) |
| "Renal functional changes in diabetic nephropathy conventionally have been linked to progression of urinary albumin excretion." | 2.44 | Between hyperfiltration and impairment: demystifying early renal functional changes in diabetic nephropathy. ( Ficociello, LH; Krolewski, AS; Niewczas, MA; Perkins, BA; Rosolowsky, ET; Warram, JH, 2008) |
| "In total, 673 patients with type 2 diabetes met the inclusion criteria." | 1.91 | The Triglyceride Glucose (TyG) Index as a Sensible Marker for Identifying Insulin Resistance and Predicting Diabetic Kidney Disease. ( Li, HF; Li, Y; Miao, X, 2023) |
| "Febuxostat (5 mg/kg) was administered to streptozotocin (STZ)-treated 8-week-old male C57BL/6 mice via intraperitoneal injection for 8 weeks." | 1.91 | Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway. ( Chang, YK; Choi, WJ; Hong, YA; Kim, SY; Park, CW; Yang, KJ, 2023) |
| "Collectively, Gln attenuates diabetic nephropathy and other complications in type 2 diabetes mellitus in rats through its antioxidant and anti-inflammatory activities." | 1.91 | Exogenous glutamine ameliorates diabetic nephropathy in a rat model of type 2 diabetes mellitus through its antioxidant and anti-inflammatory activities. ( Adibhesami, G; Ahmadvand, H; Babaeenezhad, E; Mahdavifard, S; Nasri, M, 2023) |
| "Fifty-five patients with type II diabetes mellitus were divided into two groups: case and control." | 1.91 | Serum Levels of Indoxyl Sulfate and P-cresol in Type II Diabetic Patients With and Without Nephropathy. ( Aliasgharzadeh, A; Jouyban, A; Moradi, M; Oladi-Ghadikolaei, R; Shayanfar, A; Soleymani, J; Tayebi Khosroshahi, H, 2023) |
| "Incidence rate for ESRD among patients with no episodes of AKI and one, two, and three or more episodes of AKI was 7." | 1.72 | Clinical Predictors and Long-term Impact of Acute Kidney Injury on Progression of Diabetic Kidney Disease in Chinese Patients With Type 2 Diabetes. ( Chan, JCN; Cheng, YL; Chow, CC; Chow, EYK; Fan, B; Fung, S; Hiu, G; Huang, Y; Jiang, G; Kam, G; Kong, APS; Lan, HY; Lau, E; Lau, ES; Lau, IT; Lau, KP; Lee, KF; Leung, JY; Li, JK; Lim, CKP; Lo, S; Luk, AO; Ma, RCW; Oram, RA; Ozaki, R; Siu, SC; So, WY; Szeto, CC; Tam, CHT; Tang, NLS; Tsang, CC; Tsang, MW; Yeung, VT, 2022) |
| "Diabetic nephropathy is one of the chronic microvascular complications of diabetes and is a leading cause of end-stage renal disease." | 1.72 | Sodium-glucose Cotransporter Type 2 Inhibitors: A New Insight into the Molecular Mechanisms of Diabetic Nephropathy. ( Li, N; Zhou, H, 2022) |
| "Early diagnosis of diabetic nephropathy (DN), the leading cause of death in diabetic patients, is an important issue in preventing and reducing the disease burden for patients and the healthcare system." | 1.72 | Value of Color Doppler Ultrasonography for Diagnosing Early Diabetic Nephropathy. ( Geng, X; Guo, Y; Ke, L, 2022) |
| "299 patients with type 2 diabetes mellitus (T2DM) hospitalized in the Second Affiliated Hospital of Soochow University were enrolled." | 1.72 | Genomic DNA Methylation in Diabetic Chronic Complications in Patients With Type 2 Diabetes Mellitus. ( Hu, J; Jiang, M; Wang, X; Yang, W; Zhang, HH; Zhang, S; Zhu, Y, 2022) |
| "Hyperuricemia was categorized as a serum uric acid level ≥ 420 umol/L (7 mg/dL)." | 1.72 | Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease. ( Cui, Z; Fan, X; Li, Q; Liu, H; Shao, X; Wang, T; Yu, P; Zhou, S, 2022) |
| "Hydralazine is an antihypertensive agent and may act as a xanthine oxidase (XO) inhibitor to reduce uric acid levels in a mouse renal injury model." | 1.72 | Antioxidation and Nrf2-mediated heme oxygenase-1 activation contribute to renal protective effects of hydralazine in diabetic nephropathy. ( Chang, TT; Chen, C; Chen, JW; Chiang, CH; Lee, HJ; Lin, SC, 2022) |
| "Diabetic nephropathy is reported to occur as a result of the interactions between several pathophysiological disturbances, as well as renal oxidative stress and inflammation." | 1.62 | Malaysian Propolis and Metformin Synergistically Mitigate Kidney Oxidative Stress and Inflammation in Streptozotocin-Induced Diabetic Rats. ( Abu Bakar, AB; Jalil, NAC; Mohamed, M; Nna, VU; Othman, ZA; Zakaria, Z, 2021) |
| "Hyperuricemia has been recognized as a risk factor for insulin resistance as well as one of the factors leading to diabetic kidney disease (DKD)." | 1.51 | Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice. ( Asano, T; Fujishiro, M; Inoue, MK; Kikuchi, T; Kushiyama, A; Masaki, T; Matsunaga, Y; Mizuno, Y; Morii, K; Nakatsu, Y; Ono, H; Sakoda, H; Sasaki, K; Takahashi, M; Ueda, K; Yamamotoya, T, 2019) |
| "We recruited 98 Taiwanese patients with type 2 diabetes and 10 patients with early chronic kidney disease (CKD) into this study." | 1.51 | Serum and urinary SOD3 in patients with type 2 diabetes: comparison with early chronic kidney disease patients and association with development of diabetic nephropathy. ( Chen, CM; Chen, HL; Kuo, CW; Tu, MY, 2019) |
| "Hyperuricemia was common in youth with T2D." | 1.51 | Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An Observational Analysis From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Stu ( Bjornstad, P; El Ghormli, L; Laffel, L; Lynch, J; Nadeau, KJ; Tollefsen, SE; Weinstock, RS, 2019) |
| "Therefore, Sar can markedly ameliorate diabetic nephropathy in rats via inhibition of NLRP3 inflammasome activation and AGEs-RAGE interaction." | 1.48 | Protective effects of sarsasapogenin against early stage of diabetic nephropathy in rats. ( Chen, YJ; Hao, YC; Kong, L; Liu, YW; Wang, TY; Yin, SY; Zhang, MY, 2018) |
| "Early detection diabetic nephropathy (DN) is important." | 1.43 | Serum uric acid and its association with hypertension, early nephropathy and chronic kidney disease in type 2 diabetic patients. ( Fathy, H; Fouad, M; Zidan, A, 2016) |
| "Uric acid was positively correlated with albuminuria and creatinine levels (p < 0." | 1.42 | Uric Acid is independently associated with diabetic kidney disease: a cross-sectional study in a Chinese population. ( Bao, Y; Hu, C; Jia, W; Jiang, F; Sun, X; Tu, Y; Wang, J; Wang, S; Wang, T; Yan, D; Zhang, R, 2015) |
| "Hyperuricemia has been reported to affect renal hemodynamics in rat models." | 1.42 | Relationship between serum uric acid levels and intrarenal hemodynamic parameters. ( Ichii, M; Inaba, M; Ishimura, E; Mori, K; Nakatani, S; Nakatani, T; Ochi, A; Ohno, Y; Tsuda, A; Uchida, J; Uedono, H; Yasumoto, M, 2015) |
| "Sixty patients with type 2 diabetes mellitus were enrolled to the study." | 1.40 | Association of serum uric acid with level of blood pressure in type 2 diabetic patients. ( Behradmanesh, S; Kheiri, S; Nasri, H; Rafieian-Kopaei, M, 2014) |
| "Diabetic nephropathy is the kidney disease that occurs as a result of diabetes." | 1.40 | Protective effect of bioflavonoid myricetin enhances carbohydrate metabolic enzymes and insulin signaling molecules in streptozotocin-cadmium induced diabetic nephrotoxic rats. ( Ashokkumar, N; Kandasamy, N, 2014) |
| "147 patients (61 women and 86 men) with type 1 diabetes without increased urine albumin excretion were analysed." | 1.40 | Serum uric acid concentration is associated with early changes of glomerular filtration rate in patients with diabetes type 1 without increased albumin excretion. ( Korzeniewska-Dyl, I; Moczulski, D; Spaleniak, S, 2014) |
| "Eighteen rats with diabetic nephropathy and 6 rats without induced nephropathy were divided into 4 groups, each containing 6 animals." | 1.39 | Effect of silymarin on streptozotocin-nicotinamide-induced type 2 diabetic nephropathy in rats. ( Jose, MA; Kumar, BN; Sathyamurthy, D; Sheela, N, 2013) |
| "Lovastatin, 20 mg/d, was administered for 90 days." | 1.38 | Effect of lovastatin therapy and withdrawal on serum uric acid level in people with type 2 diabetic nephropathy. ( Davari-Farid, S; Ghorashi, S; Hashemi-Aghdam, Y; Khosraviani, K; Nargabad, ON; Nezami, N; Safa, J; Salari, B; Tabrizi, JS, 2012) |
| "The treatment of quercetin and allopurinol regulated renal urate transport-related proteins to reduce hyperuricemia, and lipid metabolism-related genes to alleviate kidney lipid accumulation in STZ-treated rats." | 1.38 | Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation. ( Kong, LD; Pan, Y; Wang, C; Wang, FM; Zhang, QY, 2012) |
| "KK-A(y)/Ta mice, an animal model of type 2 diabetes, were provided access to either regular drinking water or drinking water containing 10 mg/dl of allopurinol." | 1.38 | Reducing serum uric acid attenuates TGF-β1-induced profibrogenic progression in type 2 diabetic nephropathy. ( Choi, YW; Ihm, CG; Jeong, KH; Kim, SM; Lee, SH; Lee, TW; Lim, SJ; Moon, JY; Seok, HY, 2012) |
| "By analysing factors associated with diabetic nephropathy rather than microvascular disease in general, this study provides evidence that night-time diastolic BP and a relative increase in platelet count are associated with incipient diabetic nephropathy." | 1.38 | Factors associated with diabetic nephropathy in subjects with proliferative retinopathy. ( Buhagiar, G; Calleja, N; Fava, S; Magri, CJ; Vassallo, J, 2012) |
| "INTRODUCTION." | 1.37 | Hyperuricemia and albuminuria in patients with type 2 diabetes mellitus. ( Bonakdaran, S; Hami, M; Shakeri, MT, 2011) |
| "The major causes of ESRD included diabetes mellitus and hypertension seen in 37 (74%) and 10 patients (20%), respectively." | 1.36 | Beta-2 microglobulin levels in hemodialysis patients. ( Anees, M; Bilal, M; Ibrahim, M; Mumtaz, A, 2010) |
| "Allopurinol treatment significantly lowered uric acid levels, reduced albuminuria, and ameliorated tubulointerstitial injury, but it did not prevent mesangial expansion." | 1.35 | Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. ( Heinig, M; Johnson, RJ; Kosugi, T; Nakagawa, T; Nakayama, T; Roncal, C; Sanchez-Lozada, LG; Yuzawa, Y; Zhang, L, 2009) |
| "Uric acid was measured 3 years after onset of diabetes and before any patient developed microalbuminuria." | 1.35 | Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. ( Hovind, P; Johnson, RJ; Parving, HH; Rossing, P; Tarnow, L, 2009) |
| "Patients with type 1 diabetes and normoalbuminuria or microalbuminuria were recruited to the Second Joslin Kidney Study." | 1.35 | High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. ( Binns, AL; Ficociello, LH; Krolewski, AS; Maselli, NJ; Niewczas, MA; Roshan, B; Rosolowsky, ET; Warram, JH, 2008) |
| "Hyperuricemia is a common feature in patients with chronic kidney disease (CKD)." | 1.33 | J-shaped mortality relationship for uric acid in CKD. ( Axelsson, J; Bárány, P; Carrero, JJ; García-López, E; Heimbürger, O; Johnson, RJ; Lindholm, B; Molinaei, H; Qureshi, AR; Stenvinkel, P; Suliman, ME, 2006) |
| "We conclude that PIDDM patients have more severe renal dysfunction than NIDDM patients and, since glycosylated haemoglobin concentrations are comparable in these groups, we attribute this to a renal insult due to malnutrition predating the onset of the PIDDM." | 1.30 | Kidney function in phasic insulin dependent diabetes mellitus in Jamaica. ( Bennett, F; Morrison, EY; Ragoobirsingh, D, 1997) |
| "The plasma of NIDDM patients with CHD had a significantly higher value of unidentified antioxidative potential than that of patients without CHD." | 1.30 | The association between the total antioxidant potential of plasma and the presence of coronary heart disease and renal dysfunction in patients with NIDDM. ( Alho, H; Koivula, T; Lehtimäki, T; Leinonen, J; Pasternack, A; Rantalaiho, V; Wirta, O, 1998) |
| "The uric acid tubular load was similar in both groups (2." | 1.29 | [Renal hypouricemia in juvenile diabetes mellitus]. ( Casero Ariza, J; Durá Travé, T; Moya Benavent, M, 1996) |
| "Of 201 NIDDM patients without a diminished glomerular filtration rate, 66 patients (32." | 1.28 | Diabetic hypouricemia as an indicator of clinical nephropathy. ( Iwamoto, H; Marumo, F; Shichiri, M, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (5.75) | 18.7374 |
| 1990's | 12 (6.90) | 18.2507 |
| 2000's | 17 (9.77) | 29.6817 |
| 2010's | 91 (52.30) | 24.3611 |
| 2020's | 44 (25.29) | 2.80 |
| Authors | Studies |
|---|---|
| Shibata, Y | 1 |
| Yamazaki, M | 1 |
| Kitahara, J | 1 |
| Okubo, Y | 1 |
| Oiwa, A | 1 |
| Sato, A | 1 |
| Komatsu, M | 2 |
| Lai, YJ | 1 |
| Chen, YY | 1 |
| Ku, PW | 1 |
| Chen, LJ | 1 |
| Yen, YF | 1 |
| Jiang, G | 1 |
| Luk, AO | 1 |
| Tam, CHT | 1 |
| Ozaki, R | 1 |
| Lim, CKP | 1 |
| Chow, EYK | 1 |
| Lau, ES | 1 |
| Kong, APS | 1 |
| Fan, B | 1 |
| Lee, KF | 1 |
| Siu, SC | 1 |
| Hiu, G | 1 |
| Tsang, CC | 1 |
| Lau, KP | 1 |
| Leung, JY | 1 |
| Tsang, MW | 1 |
| Kam, G | 1 |
| Lau, IT | 1 |
| Li, JK | 1 |
| Yeung, VT | 1 |
| Lau, E | 1 |
| Lo, S | 1 |
| Fung, S | 1 |
| Cheng, YL | 1 |
| Chow, CC | 1 |
| Tang, NLS | 1 |
| Huang, Y | 1 |
| Lan, HY | 1 |
| Oram, RA | 1 |
| Szeto, CC | 1 |
| So, WY | 1 |
| Chan, JCN | 1 |
| Ma, RCW | 1 |
| Hassan Al-Bayati, AA | 1 |
| Jawad Al-Khateeb, SM | 1 |
| Wu, B | 1 |
| Chen, L | 2 |
| Xu, Y | 2 |
| Duan, Q | 1 |
| Zheng, Z | 2 |
| He, D | 1 |
| Ji, P | 1 |
| Zhu, J | 2 |
| Feng, J | 2 |
| Li, H | 1 |
| Yu, Q | 2 |
| Qin, H | 1 |
| Wei, L | 1 |
| Zhang, J | 2 |
| Chang, TT | 1 |
| Chiang, CH | 1 |
| Chen, C | 1 |
| Lin, SC | 1 |
| Lee, HJ | 1 |
| Chen, JW | 1 |
| Li, N | 2 |
| Zhou, H | 1 |
| Ma, Y | 1 |
| Wang, Q | 3 |
| Chen, Y | 4 |
| Su, J | 1 |
| Gao, Q | 2 |
| Fan, Y | 2 |
| Liu, M | 1 |
| He, Q | 1 |
| Wang, X | 4 |
| Yang, W | 1 |
| Zhu, Y | 1 |
| Zhang, S | 1 |
| Jiang, M | 1 |
| Hu, J | 1 |
| Zhang, HH | 1 |
| Bai, F | 1 |
| Li, R | 1 |
| Ke, L | 1 |
| Guo, Y | 1 |
| Geng, X | 1 |
| Chen, XM | 1 |
| Lin, GX | 1 |
| Ma, HY | 1 |
| Wang, RS | 1 |
| Wang, SM | 1 |
| Tang, D | 1 |
| Li, Q | 5 |
| Shao, X | 3 |
| Zhou, S | 3 |
| Cui, Z | 3 |
| Liu, H | 5 |
| Wang, T | 5 |
| Fan, X | 4 |
| Yu, P | 3 |
| Zhu, L | 1 |
| Sun, J | 1 |
| Tian, R | 1 |
| Zhou, Y | 1 |
| Yu, J | 1 |
| An, X | 1 |
| Osonoi, T | 1 |
| Saito, M | 1 |
| Hosoya, M | 1 |
| Douguchi, S | 1 |
| Ofuchi, K | 1 |
| Katoh, M | 1 |
| Yang, KJ | 1 |
| Choi, WJ | 1 |
| Chang, YK | 1 |
| Park, CW | 1 |
| Kim, SY | 2 |
| Hong, YA | 1 |
| Pei, Y | 1 |
| Shu, Y | 1 |
| Deng, B | 1 |
| Liu, Y | 2 |
| Aktas, G | 2 |
| Yilmaz, S | 1 |
| Kantarci, DB | 1 |
| Duman, TT | 2 |
| Bilgin, S | 1 |
| Balci, SB | 1 |
| Atak Tel, BM | 1 |
| Lin, Z | 2 |
| Zhang, D | 2 |
| Zhang, X | 1 |
| Guo, W | 1 |
| Wang, W | 2 |
| Zhang, Y | 2 |
| Liu, Z | 1 |
| Bi, Y | 1 |
| Wu, M | 1 |
| Lu, X | 1 |
| Jiang, J | 3 |
| Zhou, X | 3 |
| Lan, L | 3 |
| Weng, J | 1 |
| Ren, W | 3 |
| Zhang, T | 1 |
| Yang, Y | 1 |
| Yang, C | 1 |
| Wei, H | 1 |
| Zhao, Q | 1 |
| Oladi-Ghadikolaei, R | 1 |
| Aliasgharzadeh, A | 1 |
| Shayanfar, A | 1 |
| Soleymani, J | 1 |
| Moradi, M | 1 |
| Jouyban, A | 1 |
| Tayebi Khosroshahi, H | 1 |
| Li, HF | 1 |
| Miao, X | 1 |
| Li, Y | 4 |
| Mizuno, Y | 1 |
| Yamamotoya, T | 1 |
| Nakatsu, Y | 1 |
| Ueda, K | 1 |
| Matsunaga, Y | 1 |
| Inoue, MK | 1 |
| Sakoda, H | 1 |
| Fujishiro, M | 1 |
| Ono, H | 1 |
| Kikuchi, T | 1 |
| Takahashi, M | 2 |
| Morii, K | 1 |
| Sasaki, K | 1 |
| Masaki, T | 1 |
| Asano, T | 1 |
| Kushiyama, A | 1 |
| Huang, JX | 1 |
| Liao, YF | 1 |
| Li, YM | 1 |
| Kocak, MZ | 1 |
| Atak, BM | 1 |
| Savli, H | 1 |
| Wan, H | 1 |
| Wang, Y | 4 |
| Fang, S | 1 |
| Zhang, W | 1 |
| Xia, F | 1 |
| Wang, N | 2 |
| Lu, Y | 2 |
| Tanaka, M | 2 |
| Yamakage, H | 1 |
| Inoue, T | 1 |
| Odori, S | 1 |
| Kusakabe, T | 1 |
| Shimatsu, A | 1 |
| Satoh-Asahara, N | 1 |
| Xia, Q | 1 |
| Zhang, SH | 1 |
| Yang, SM | 1 |
| Zhu, XL | 1 |
| Su, S | 1 |
| Hu, AP | 1 |
| Li, DM | 1 |
| Nakagawa, T | 4 |
| Johnson, RJ | 9 |
| Andres-Hernando, A | 1 |
| Roncal-Jimenez, C | 1 |
| Sanchez-Lozada, LG | 2 |
| Tolan, DR | 1 |
| Lanaspa, MA | 4 |
| Sun, X | 3 |
| Liu, J | 2 |
| Wang, G | 1 |
| Lee, WL | 1 |
| Wang, PH | 1 |
| Doria, A | 5 |
| Galecki, AT | 2 |
| Spino, C | 1 |
| Pop-Busui, R | 2 |
| Cherney, DZ | 3 |
| Lingvay, I | 1 |
| Parsa, A | 1 |
| Rossing, P | 7 |
| Sigal, RJ | 1 |
| Afkarian, M | 1 |
| Aronson, R | 1 |
| Caramori, ML | 1 |
| Crandall, JP | 1 |
| de Boer, IH | 1 |
| Elliott, TG | 1 |
| Goldfine, AB | 1 |
| Haw, JS | 1 |
| Hirsch, IB | 1 |
| Karger, AB | 1 |
| Maahs, DM | 7 |
| McGill, JB | 1 |
| Molitch, ME | 1 |
| Perkins, BA | 4 |
| Polsky, S | 1 |
| Pragnell, M | 1 |
| Robiner, WN | 1 |
| Rosas, SE | 1 |
| Senior, P | 1 |
| Tuttle, KR | 1 |
| Umpierrez, GE | 1 |
| Wallia, A | 1 |
| Weinstock, RS | 2 |
| Wu, C | 1 |
| Mauer, M | 4 |
| Badve, SV | 1 |
| Pascoe, EM | 1 |
| Tiku, A | 1 |
| Boudville, N | 1 |
| Brown, FG | 1 |
| Cass, A | 1 |
| Clarke, P | 1 |
| Dalbeth, N | 1 |
| Day, RO | 1 |
| de Zoysa, JR | 1 |
| Douglas, B | 1 |
| Faull, R | 1 |
| Harris, DC | 1 |
| Hawley, CM | 1 |
| Jones, GRD | 1 |
| Kanellis, J | 1 |
| Palmer, SC | 1 |
| Perkovic, V | 1 |
| Rangan, GK | 1 |
| Reidlinger, D | 1 |
| Robison, L | 1 |
| Walker, RJ | 1 |
| Walters, G | 1 |
| Johnson, DW | 1 |
| Zou, L | 1 |
| Qiu, J | 1 |
| Yu, R | 1 |
| Itano, S | 1 |
| Kadoya, H | 1 |
| Satoh, M | 1 |
| Nakamura, T | 1 |
| Murase, T | 1 |
| Sasaki, T | 2 |
| Kanwar, YS | 1 |
| Kashihara, N | 1 |
| Nasri, M | 1 |
| Adibhesami, G | 1 |
| Mahdavifard, S | 1 |
| Babaeenezhad, E | 1 |
| Ahmadvand, H | 1 |
| Hou, L | 1 |
| Shi, Y | 2 |
| Wang, S | 4 |
| Chen, Q | 1 |
| Zhao, M | 1 |
| Wen, L | 1 |
| Yang, H | 2 |
| Ma, L | 1 |
| Fu, P | 1 |
| Feng, X | 1 |
| Huang, J | 1 |
| Peng, Y | 1 |
| Nna, VU | 1 |
| Abu Bakar, AB | 1 |
| Zakaria, Z | 1 |
| Othman, ZA | 1 |
| Jalil, NAC | 1 |
| Mohamed, M | 1 |
| Piani, F | 1 |
| Melena, I | 1 |
| Severn, C | 1 |
| Chung, LT | 1 |
| Vinovskis, C | 1 |
| Cherney, D | 2 |
| Pyle, L | 2 |
| Roncal-Jimenez, CA | 1 |
| Rewers, A | 1 |
| van Raalte, DH | 1 |
| Obeid, W | 1 |
| Parikh, C | 1 |
| Nelson, RG | 1 |
| Pavkov, ME | 1 |
| Nadeau, KJ | 2 |
| Bjornstad, P | 5 |
| Gul, A | 2 |
| Harford, A | 1 |
| Zager, P | 2 |
| Ceriello, A | 2 |
| De Cosmo, S | 2 |
| Rossi, MC | 1 |
| Lucisano, G | 1 |
| Genovese, S | 1 |
| Pontremoli, R | 2 |
| Fioretto, P | 2 |
| Giorda, C | 2 |
| Pacilli, A | 1 |
| Viazzi, F | 2 |
| Russo, G | 1 |
| Nicolucci, A | 1 |
| Han, Y | 1 |
| Zhang, M | 2 |
| Lu, J | 2 |
| Zhang, L | 2 |
| Han, J | 1 |
| Zhao, F | 1 |
| Chen, H | 1 |
| Bao, Y | 3 |
| Jia, W | 3 |
| Zeng, C | 1 |
| Cheng, D | 1 |
| Sheng, X | 1 |
| Jian, G | 1 |
| Li, J | 2 |
| Bao, H | 1 |
| Li, C | 2 |
| Zhi, X | 1 |
| Peng, L | 2 |
| Han, H | 1 |
| Sun, B | 1 |
| Bai, Y | 1 |
| Yang, R | 1 |
| Song, Y | 1 |
| Pilemann-Lyberg, S | 3 |
| Persson, F | 2 |
| Frystyk, J | 2 |
| Wada, T | 1 |
| Hosoya, T | 1 |
| Honda, D | 1 |
| Sakamoto, R | 1 |
| Narita, K | 1 |
| Okui, D | 1 |
| Kimura, K | 1 |
| Toyoda, K | 1 |
| Suzuki, Y | 1 |
| Muta, K | 1 |
| Masuyama, T | 1 |
| Kakimoto, K | 1 |
| Kobayashi, A | 1 |
| Shoda, T | 1 |
| Sugai, S | 1 |
| Li, GX | 1 |
| Jiao, XH | 1 |
| Cheng, XB | 1 |
| Słomiński, B | 1 |
| Skrzypkowska, M | 1 |
| Ryba-Stanisławowska, M | 1 |
| Brandt, A | 1 |
| Chai, T | 1 |
| Li, Z | 2 |
| Hansen, TW | 2 |
| Theilade, S | 2 |
| Singh Ahluwalia, T | 1 |
| Liu, YW | 1 |
| Hao, YC | 1 |
| Chen, YJ | 1 |
| Yin, SY | 1 |
| Zhang, MY | 1 |
| Kong, L | 1 |
| Wang, TY | 1 |
| Suyoto, PST | 1 |
| Liu, X | 1 |
| Ma, J | 2 |
| Hu, MT | 1 |
| Dong, XD | 1 |
| Xiang, LT | 1 |
| Gu, QR | 1 |
| Du, ZY | 1 |
| Chen, SM | 1 |
| Chen, GR | 1 |
| Wang, J | 3 |
| Yu, Y | 1 |
| Li, X | 3 |
| Li, D | 1 |
| Xu, C | 1 |
| Yuan, J | 1 |
| Wei, S | 1 |
| Yang, K | 1 |
| Zheng, D | 1 |
| Tang, Y | 1 |
| Wu, T | 1 |
| He, M | 1 |
| Zhou, XW | 1 |
| Fei, YY | 1 |
| Jiang, JL | 1 |
| Ye, SD | 1 |
| Ren, Y | 1 |
| Gao, L | 2 |
| Guo, X | 1 |
| Huo, X | 1 |
| Ji, L | 1 |
| Yang, X | 1 |
| Kuo, CW | 1 |
| Chen, HL | 1 |
| Tu, MY | 1 |
| Chen, CM | 1 |
| Lai, X | 1 |
| Tong, D | 1 |
| Ai, X | 1 |
| Wu, J | 1 |
| Luo, Y | 1 |
| Zuo, F | 1 |
| Wei, Z | 1 |
| Huang, W | 1 |
| Jiang, Q | 1 |
| Meng, X | 1 |
| Zeng, Y | 1 |
| Wang, P | 1 |
| Russo, GT | 1 |
| Kuriyama, S | 1 |
| Wang, YJ | 1 |
| Hao, CM | 1 |
| Tofte, N | 1 |
| Winther, SA | 1 |
| Ahluwalia, TS | 1 |
| Chen, MY | 1 |
| Wang, AP | 1 |
| Wang, JW | 1 |
| Ke, JF | 1 |
| Yu, TP | 1 |
| Li, LX | 1 |
| Jia, WP | 1 |
| Laffel, L | 1 |
| Lynch, J | 1 |
| El Ghormli, L | 1 |
| Tollefsen, SE | 1 |
| Meng, Y | 1 |
| Bai, H | 1 |
| Yan, J | 1 |
| Zhao, L | 1 |
| Chunlei, Y | 1 |
| Liubao, G | 1 |
| Tao, W | 1 |
| Changying, X | 1 |
| Jiao, X | 1 |
| Zhang, G | 2 |
| Li, G | 1 |
| Yin, X | 1 |
| Shen, X | 1 |
| Guarda, NS | 1 |
| Bollick, YS | 1 |
| de Carvalho, JAM | 1 |
| Premaor, MO | 1 |
| Comim, FV | 1 |
| Moresco, RN | 1 |
| Weir, MR | 1 |
| Sheela, N | 1 |
| Jose, MA | 1 |
| Sathyamurthy, D | 1 |
| Kumar, BN | 1 |
| Caramori, L | 1 |
| Gao, C | 1 |
| Jalal, D | 2 |
| Shao, HL | 1 |
| Song, CQ | 1 |
| Xu, DH | 1 |
| Shang, XJ | 1 |
| Hao, ZH | 1 |
| Yuste, C | 1 |
| Barraca, D | 1 |
| Aragoncillo-Sauco, I | 1 |
| Vega-Martínez, A | 1 |
| Abad, S | 1 |
| Verdalles-Guzmán, Ú | 1 |
| Ruiz-Caro, C | 1 |
| Ampuero, J | 1 |
| López-Gómez, JM | 1 |
| Gilbert, RE | 1 |
| Sheikhbahaei, S | 1 |
| Fotouhi, A | 1 |
| Hafezi-Nejad, N | 1 |
| Nakhjavani, M | 1 |
| Esteghamati, A | 1 |
| Bao, YS | 1 |
| Jia, XB | 1 |
| Ji, Y | 1 |
| Yang, J | 1 |
| Zhao, SL | 1 |
| Na, SP | 1 |
| Zhou, J | 1 |
| Song, HL | 1 |
| Yang, FJ | 1 |
| Huang, HJ | 1 |
| Li, SQ | 1 |
| Rafieian-Kopaei, M | 1 |
| Behradmanesh, S | 1 |
| Kheiri, S | 1 |
| Nasri, H | 1 |
| Ran, J | 1 |
| Tan, R | 1 |
| Lao, G | 1 |
| Verdoia, M | 1 |
| Schaffer, A | 1 |
| Barbieri, L | 1 |
| Di Giovine, G | 1 |
| Marino, P | 1 |
| De Luca, G | 1 |
| Kandasamy, N | 1 |
| Ashokkumar, N | 1 |
| Balakumar, P | 1 |
| Varatharajan, R | 1 |
| Nyo, YH | 1 |
| Renushia, R | 1 |
| Raaginey, D | 1 |
| Oh, AN | 1 |
| Akhtar, SS | 1 |
| Rupeshkumar, M | 1 |
| Sundram, K | 1 |
| Dhanaraj, SA | 1 |
| Uchida, S | 1 |
| Sugawara, M | 1 |
| Saito, T | 1 |
| Nakai, K | 1 |
| Fujita, M | 1 |
| Mochizuki, K | 1 |
| Shin, I | 1 |
| Morita, T | 1 |
| Hikita, T | 1 |
| Itakura, H | 1 |
| Takahashi, Y | 1 |
| Mizuno, S | 1 |
| Ohno, Y | 2 |
| Ito, K | 1 |
| Ito, T | 1 |
| Soma, M | 1 |
| Spaleniak, S | 1 |
| Korzeniewska-Dyl, I | 1 |
| Moczulski, D | 1 |
| Lytvyn, Y | 1 |
| Wang, C | 3 |
| Liu, F | 1 |
| Cheng, J | 1 |
| Kim, SM | 2 |
| Lee, SH | 2 |
| Kim, YG | 1 |
| Seo, JW | 1 |
| Choi, YW | 2 |
| Kim, DJ | 1 |
| Jeong, KH | 2 |
| Lee, TW | 2 |
| Ihm, CG | 2 |
| Won, KY | 1 |
| Moon, JY | 2 |
| Yan, D | 2 |
| Tu, Y | 1 |
| Jiang, F | 2 |
| Zhang, R | 2 |
| Hu, C | 2 |
| Ishimoto, T | 1 |
| Kosugi, T | 3 |
| Kume, S | 1 |
| Snell-Bergeon, JK | 3 |
| Uedono, H | 1 |
| Tsuda, A | 1 |
| Ishimura, E | 2 |
| Yasumoto, M | 1 |
| Ichii, M | 1 |
| Ochi, A | 1 |
| Nakatani, S | 1 |
| Mori, K | 2 |
| Uchida, J | 1 |
| Nakatani, T | 1 |
| Inaba, M | 2 |
| Wang, L | 2 |
| Cheng, JF | 1 |
| Sun, LP | 1 |
| Song, YX | 1 |
| Guo, LH | 1 |
| Xu, JM | 1 |
| Wu, TF | 1 |
| Mohan, C | 1 |
| Peng, A | 1 |
| Xu, HX | 1 |
| Liu, XY | 1 |
| Liu, P | 1 |
| Liu, R | 1 |
| Chen, X | 1 |
| Wang, D | 1 |
| Zhang, F | 1 |
| Xiao, F | 1 |
| Hu, YG | 1 |
| Wu, SN | 1 |
| Shou, QY | 1 |
| Cai, YQ | 1 |
| Wang, HM | 1 |
| Wang, H | 2 |
| Jia, G | 1 |
| Di, F | 1 |
| Shao, J | 1 |
| Roncal, C | 2 |
| Milagres, T | 1 |
| Bishop, FK | 1 |
| Wadwa, RP | 1 |
| Xia, X | 1 |
| Zhao, C | 1 |
| Peng, FF | 1 |
| Luo, QM | 1 |
| Zhou, Q | 1 |
| Lin, ZC | 1 |
| Yu, XQ | 1 |
| Huang, FX | 1 |
| Hayashino, Y | 1 |
| Okamura, S | 1 |
| Tsujii, S | 1 |
| Ishii, H | 1 |
| Peng, D | 1 |
| He, Z | 1 |
| Kato, S | 1 |
| Ando, M | 1 |
| Mizukoshi, T | 1 |
| Nagata, T | 1 |
| Katsuno, T | 1 |
| Tsuboi, N | 1 |
| Maruyama, S | 1 |
| Pourfarjam, Y | 1 |
| Rezagholizadeh, L | 1 |
| Nowrouzi, A | 1 |
| Meysamie, A | 1 |
| Ghaseminejad, S | 1 |
| Ziamajidi, N | 1 |
| Norouzi, D | 1 |
| Fouad, M | 1 |
| Fathy, H | 1 |
| Zidan, A | 1 |
| Gu, L | 1 |
| Huang, L | 1 |
| Wu, H | 1 |
| Lou, Q | 1 |
| Bian, R | 1 |
| Ahola, AJ | 1 |
| Sandholm, N | 1 |
| Forsblom, C | 1 |
| Harjutsalo, V | 1 |
| Dahlström, E | 1 |
| Groop, PH | 1 |
| Rosolowsky, ET | 2 |
| Niewczas, MA | 2 |
| Ficociello, LH | 2 |
| Warram, JH | 2 |
| Krolewski, AS | 3 |
| Xia, JF | 1 |
| Liang, QL | 1 |
| Hu, P | 1 |
| Wang, YM | 1 |
| Li, P | 1 |
| Luo, GA | 1 |
| Hovind, P | 3 |
| Tarnow, L | 1 |
| Parving, HH | 3 |
| Nakayama, T | 1 |
| Heinig, M | 1 |
| Yuzawa, Y | 1 |
| Liu, S | 1 |
| Liu, Q | 1 |
| Wang, XM | 1 |
| Duan, H | 1 |
| Jalal, DI | 2 |
| Rivard, CJ | 1 |
| McFann, K | 1 |
| Rewers, M | 1 |
| Rotimi, SO | 1 |
| Olayiwola, I | 1 |
| Ademuyiwa, O | 1 |
| Adamson, I | 1 |
| Maalouf, NM | 2 |
| Cameron, MA | 2 |
| Moe, OW | 2 |
| Sakhaee, K | 2 |
| Mumtaz, A | 1 |
| Anees, M | 1 |
| Bilal, M | 1 |
| Ibrahim, M | 1 |
| Bonakdaran, S | 1 |
| Hami, M | 1 |
| Shakeri, MT | 1 |
| Magri, CJ | 1 |
| Calleja, N | 1 |
| Buhagiar, G | 1 |
| Fava, S | 1 |
| Vassallo, J | 1 |
| Miao, Y | 1 |
| Ottenbros, SA | 1 |
| Laverman, GD | 2 |
| Brenner, BM | 1 |
| Cooper, ME | 2 |
| Grobbee, DE | 1 |
| Shahinfar, S | 1 |
| de Zeeuw, D | 2 |
| Lambers Heerspink, HJ | 2 |
| McIntyre, NJ | 1 |
| Fluck, RJ | 1 |
| McIntyre, CW | 1 |
| Taal, MW | 1 |
| Resl, M | 1 |
| Clodi, M | 1 |
| Neuhold, S | 1 |
| Kromoser, H | 1 |
| Riedl, M | 1 |
| Vila, G | 1 |
| Prager, R | 1 |
| Pacher, R | 1 |
| Strunk, G | 1 |
| Luger, A | 1 |
| Hülsmann, M | 1 |
| Altemtam, N | 1 |
| Russell, J | 1 |
| El Nahas, M | 1 |
| Dhaun, N | 1 |
| Webb, DJ | 1 |
| Smink, PA | 1 |
| Bakker, SJ | 1 |
| Berl, T | 1 |
| Nezami, N | 1 |
| Safa, J | 1 |
| Salari, B | 1 |
| Ghorashi, S | 1 |
| Khosraviani, K | 1 |
| Davari-Farid, S | 1 |
| Hashemi-Aghdam, Y | 1 |
| Nargabad, ON | 1 |
| Tabrizi, JS | 1 |
| D'Marco, L | 1 |
| García, I | 1 |
| Vega, C | 1 |
| Pan, Y | 1 |
| Zhang, QY | 1 |
| Wang, FM | 1 |
| Kong, LD | 1 |
| Imaizumi, S | 1 |
| Miura, S | 1 |
| Yahiro, E | 1 |
| Uehara, Y | 1 |
| Komuro, I | 1 |
| Saku, K | 1 |
| Katsiki, N | 1 |
| Papanas, N | 1 |
| Fonseca, VA | 1 |
| Maltezos, E | 1 |
| Mikhailidis, DP | 1 |
| Seok, HY | 1 |
| Lim, SJ | 1 |
| Sanaka, T | 1 |
| Akizawa, T | 1 |
| Koide, K | 1 |
| Koshikawa, S | 1 |
| Daudon, M | 1 |
| Lacour, B | 1 |
| Jungers, P | 1 |
| Kostrzewa-Zabłocka, E | 1 |
| Tseng, CH | 1 |
| Adams-Huet, B | 1 |
| Suliman, ME | 1 |
| García-López, E | 1 |
| Qureshi, AR | 1 |
| Molinaei, H | 1 |
| Carrero, JJ | 1 |
| Heimbürger, O | 1 |
| Bárány, P | 1 |
| Axelsson, J | 1 |
| Lindholm, B | 1 |
| Stenvinkel, P | 1 |
| Wakabayashi, I | 1 |
| Masuda, H | 1 |
| Abe, H | 1 |
| Minatoguchi, S | 1 |
| Ohashi, H | 1 |
| Murata, I | 1 |
| Minagawa, T | 1 |
| Okuma, T | 1 |
| Yokoyama, H | 1 |
| Takatsu, H | 1 |
| Takaya, T | 1 |
| Nagano, T | 1 |
| Osumi, Y | 1 |
| Kakami, M | 1 |
| Tsukamoto, T | 1 |
| Tanaka, T | 1 |
| Hiei, K | 1 |
| Fujiwara, H | 1 |
| Maselli, NJ | 1 |
| Binns, AL | 1 |
| Roshan, B | 1 |
| Fukui, M | 1 |
| Shiraishi, E | 1 |
| Harusato, I | 1 |
| Hosoda, H | 1 |
| Asano, M | 1 |
| Kadono, M | 1 |
| Hasegawa, G | 1 |
| Yoshikawa, T | 1 |
| Nakamura, N | 1 |
| Roche, S | 1 |
| Moinade, S | 1 |
| Schneider, H | 1 |
| Pastow, A | 1 |
| Rathmann, W | 1 |
| Hauner, H | 1 |
| Dannehl, K | 1 |
| Gries, FA | 1 |
| Georgadze, ZO | 1 |
| Balabolkin, MI | 1 |
| Mamaeva, GG | 1 |
| Liudina, LI | 1 |
| Mishchenko, BP | 1 |
| Arbuzova, MI | 1 |
| Bruno, G | 1 |
| Cavallo-Perin, P | 1 |
| Bargero, G | 1 |
| Borra, M | 1 |
| Calvi, V | 1 |
| D'Errico, N | 1 |
| Deambrogio, P | 1 |
| Pagano, G | 1 |
| Elbagir, MN | 1 |
| Eltom, MA | 1 |
| Mahadi, EO | 1 |
| Berne, C | 1 |
| Okada, K | 1 |
| Urae, J | 1 |
| Takahashi, S | 1 |
| Durá Travé, T | 1 |
| Moya Benavent, M | 1 |
| Casero Ariza, J | 1 |
| Ragoobirsingh, D | 1 |
| Bennett, F | 1 |
| Morrison, EY | 1 |
| Hirai, A | 1 |
| Saito, Y | 1 |
| Leinonen, J | 1 |
| Rantalaiho, V | 1 |
| Lehtimäki, T | 1 |
| Koivula, T | 1 |
| Wirta, O | 1 |
| Pasternack, A | 1 |
| Alho, H | 1 |
| Lacourcière, Y | 1 |
| Bélanger, A | 1 |
| Godin, C | 1 |
| Hallé, JP | 1 |
| Ross, S | 1 |
| Wright, N | 1 |
| Marion, J | 1 |
| Emoto, M | 1 |
| Kanda, H | 1 |
| Shoji, T | 1 |
| Kawagishi, T | 1 |
| Tahara, H | 1 |
| Okuno, Y | 1 |
| Nishizawa, Y | 1 |
| Peng, Z | 1 |
| Wang, Z | 1 |
| Peng, J | 1 |
| Shichiri, M | 2 |
| Iwamoto, H | 2 |
| Marumo, F | 1 |
| Chen, HC | 1 |
| Lai, YH | 1 |
| Tsai, CY | 1 |
| Tsai, JH | 1 |
| Shiigai, T | 1 |
| Phanichphant, S | 1 |
| Govithrapong, P | 1 |
| Keller, H | 1 |
| Martinez-Maldonado, M | 1 |
| Eknoyan, G | 1 |
| Suki, WN | 1 |
| Waters, WC | 1 |
| Raja, RM | 1 |
| Kramer, MS | 1 |
| Manchanda, R | 1 |
| Lazaro, N | 1 |
| Rosenbaum, JL | 1 |
| Mertz, P | 1 |
| Strandgaard, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy[NCT02314533] | Phase 4 | 200 participants (Anticipated) | Interventional | 2014-12-31 | Not yet recruiting | ||
| PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D[NCT02017171] | Phase 3 | 530 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial[NCT02502071] | Phase 4 | 45 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| A Population Based Cohort Study on Metabolic Syndrome Complications, and Mortality; (MetSCoM) Study[NCT02958579] | 10,000 participants (Anticipated) | Observational | 2005-01-31 | Recruiting | |||
| The Effect of Acute Fructose Load in Patients With Chronic Kidney Disease and Patients With Type 2 Diabetes Compared to Healthy Subjects[NCT03157960] | 20 participants (Actual) | Interventional | 2012-02-01 | Completed | |||
| Neutrophil Gelatinase Associated Lipocalin and Kidney Injury Molecule-1 As Biomarkers of Acute Kidney Injury in Children With Diabetic Ketoacidosis[NCT06032325] | 48 participants (Anticipated) | Observational [Patient Registry] | 2024-01-01 | Not yet recruiting | |||
| Diabetic Kidney Alarm (DKA) Study - Tubulopathy in Diabetic Ketoacidosis[NCT03128229] | 41 participants (Actual) | Observational | 2017-06-01 | Completed | |||
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347] | Phase 3 | 1,513 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| [NCT02797028] | Phase 4 | 320 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Study Protocol for a Prospective Observational Study Investigating the Role of Luminal Pressure on Arteriovenous Fistula Maturation[NCT04017806] | 60 participants (Anticipated) | Observational | 2018-09-19 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Geometric mean of urinary albumin excretion rate (AER) during the last three months of the treatment period (Visits 15 and 16), adjusted for the mean urinary AER at baseline. Results are expressed as least square means of the geometric means in each subject in each group. (NCT02017171)
Timeframe: Last three months of treatment period (Weeks 142 and 156)
| Intervention | ug/min (Least Squares Mean) |
|---|---|
| Allopurinol | 47.9 |
| Placebo | 37.4 |
Geometric mean of two urinary albumin excretion (AER) measurements at the end of the 2-month wash-out period following the 3-year treatment period, adjusted for the mean urinary AER at baseline. Results are expressed as least square means of the geometric means in each subject in each group. (NCT02017171)
Timeframe: End of the 2-month wash-out period following the 3-year treatment period (week 164)
| Intervention | ug/min (Least Squares Mean) |
|---|---|
| Allopurinol | 42.9 |
| Placebo | 31.7 |
Glomerular filtration rate (GFR) at 4 months after randomization, estimated from serum creatinine and cystatin C and adjusted for the eGFR at baseline. (NCT02017171)
Timeframe: 4 months after randomization (week 16)
| Intervention | ml/min/1.73 m2 (Least Squares Mean) |
|---|---|
| Allopurinol | 70.3 |
| Placebo | 70.0 |
Glomerular filtration rate time trajectory from baseline to end of the 2-month wash-out period (week 164) estimated from quarterly serum creatinine measurements (eGFR). eGFR slopes were estimated by a linear mixed-effects model for longitudinal eGFR measures using a multiple imputation technique for missing values. Positive values denote increasing eGFR over time, negative values denote declining eGFR over time. (NCT02017171)
Timeframe: Weeks 0, 4, 16, 32, 48, 64, 80, 96, 112, 128, 156, and 164 (from baseline to the end of washout period)
| Intervention | ml/min/1.73 m2/year (Least Squares Mean) |
|---|---|
| Allopurinol | -2.4 |
| Placebo | -2.1 |
Risk of cardiovascular events defined as the composite of CVD death (ICD-10 code I10 to I74.9), myocardial infarction, stroke (ischemic or hemorrhagic), coronary artery bypass grafting, or percutaneous coronary intervention in the allopurinol arm as compared to placebo.Results are expressed as the number of participants who experienced an event in each treatment group. The risk of an event in the allopurinol group as compared to the risk in the placebo group is expressed as hazard ratio (estimated by means of proportional hazard regression). (NCT02017171)
Timeframe: Up to the end of the 2-month wash-out period following the 3-year treatment period (week 0 to 164)
| Intervention | Participants (Count of Participants) |
|---|---|
| Allopurinol | 15 |
| Placebo | 9 |
Glomerular filtration rate (GFR) at the end of the 2-month wash-out period following the 3-year treatment period, measured by the plasma disappearance of non-radioactive iohexol (iGFR) and adjusted for the iGFR at baseline. (NCT02017171)
Timeframe: End of the 2-month wash-out period following the 3-year treatment period (week 164)
| Intervention | ml/min/1.73 m^2 (Least Squares Mean) |
|---|---|
| Allopurinol | 61.2 |
| Placebo | 61.2 |
Glomerular filtration rate (GFR) at the end of the 3-year treatment period, measured by the plasma disappearance of non-radioactive iohexol (iGFR) and adjusted for the iGFR at baseline. (NCT02017171)
Timeframe: End of the 3-yr treatment period (week 156)
| Intervention | ml/min/1.73 m2 (Least Squares Mean) |
|---|---|
| Allopurinol | 61.3 |
| Placebo | 61.0 |
Glomerular filtration rate time trajectory estimated from iohexol disappearance GFR (iGFR) measurements at weeks 0, 80, 156, and 164. iGFR slopes were estimated by a linear mixed-effects model for longitudinal iGFR measures using a multiple imputation technique for missing values. Positive values denote increasing GFR over time, negative values denote declining iGFR over time. (NCT02017171)
Timeframe: Weeks 0, 80, 156, and 164 (from baseline to the end of washout period)
| Intervention | ml/min/1.73 m2/year (Least Squares Mean) |
|---|---|
| Allopurinol | -3.0 |
| Placebo | -2.5 |
Risk of serum creatinine doubling or end stage renal disease (ESRD) in the allopurinol arm as compared to placebo. Results are expressed as the number of participants who experienced an event in each treatment group. The risk of an event in the allopurinol group as compared to the risk in the placebo group is expressed as hazard ratio (estimated by means of proportional hazard regression). (NCT02017171)
Timeframe: Up to the end of the 2-month wash-out period following the 3-year treatment period (Week 0 to Week 164)
| Intervention | Participants (Count of Participants) |
|---|---|
| Allopurinol | 13 |
| Placebo | 11 |
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
Urine uric acid crystals were identified by polarized microscopy (Polarized light imaging Zeiss Axiovert 135; 0.3NA objective), and pictures were captured from each urine sample. UA crystals were defined dichotomously as being present or absent. (NCT02502071)
Timeframe: Day 1 (pre-therapy) and Day 2 (post-therapy)
| Intervention | participants (Number) | |
|---|---|---|
| Day 1 (pre-therapy) | Day 2 (post-therapy) | |
| Sodium Bicarbonate | 14 | 3 |
Urine uric acid were evaluated using a QuantiChrom UA kit assay (DIUA-250) with quantitative colorimetric UA determination at 590 nm (BioAssay System, California, USA). (NCT02502071)
Timeframe: Day 1 (pre-therapy) and Day 2 (post-therapy)
| Intervention | mg/dl (Geometric Mean) | |
|---|---|---|
| Day 1 (pre-therapy) | Day 2 (post-therapy) | |
| Sodium Bicarbonate | 23.81 | 22.30 |
28 reviews available for uric acid and Diabetic Nephropathies
| Article | Year |
|---|---|
The Effect of Allopurinol on Renal Outcomes in Patients with Diabetic Kidney Disease: A Systematic Review and Meta-Analysis.
Topics: Albuminuria; Allopurinol; Diabetes Mellitus; Diabetic Nephropathies; Female; Humans; Kidney; Male; U | 2022 |
Serum uric acid levels and diabetic kidney disease in patients with type 2 diabetes mellitus: A dose-response meta-analysis.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Risk Factors; Uric Acid | 2022 |
Comment on: Serum uric acid levels and diabetic kidney disease in patients with type 2 diabetes mellitus: A dose-response meta-analysis.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Risk Factors; Uric Acid | 2022 |
Beneficial effects of ginsenosides on diabetic nephropathy: A systematical review and meta-analysis of preclinical evidence.
Topics: Animals; Antioxidants; Creatinine; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies | 2023 |
Fructose Production and Metabolism in the Kidney.
Topics: Animals; Cardiomegaly; Diabetic Nephropathies; Dietary Sugars; Energy Metabolism; Fatty Acids; Fruct | 2020 |
Uric acid and risk of diabetic kidney disease.
Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus; Diabetic Nephropathies; Humans; Renal Insufficienc | 2020 |
The roles of NLRP3 inflammasome-mediated signaling pathways in hyperuricemic nephropathy.
Topics: Acute Kidney Injury; Animals; Cytokines; Diabetic Nephropathies; Humans; Hyperuricemia; Inflammasome | 2021 |
Uric Acid and Diabetic Nephropathy Risk.
Topics: Allopurinol; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Disease Progression; Glomerular Filt | 2018 |
Does Altered Uric Acid Metabolism Contribute to Diabetic Kidney Disease Pathophysiology?
Topics: Diabetic Nephropathies; Disease Progression; Humans; Renal Insufficiency, Chronic; Uric Acid | 2018 |
Effect of low-carbohydrate diet on markers of renal function in patients with type 2 diabetes: A meta-analysis.
Topics: Biomarkers; Controlled Clinical Trials as Topic; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nep | 2018 |
Serum uric acid levels and decreased estimated glomerular filtration rate in patients with type 2 diabetes: A cohort study and meta-analysis.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Down-Regulation; Female; Fo | 2018 |
Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals.
Topics: Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dyslipidemias; Humans; Hypertension; | 2019 |
Protection of the kidney with sodium-glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials.
Topics: Cholesterol, LDL; Diabetic Nephropathies; Erythropoiesis; Humans; Kidney; Oxidative Stress; Randomiz | 2019 |
[The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease].
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypoglycemic Agents; Sodium-Glucose Trans | 2018 |
Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study.
Topics: Allopurinol; Clinical Trials as Topic; Diabetic Nephropathies; Humans; Kidney; Kidney Function Tests | 2013 |
Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study.
Topics: Allopurinol; Clinical Trials as Topic; Diabetic Nephropathies; Humans; Kidney; Kidney Function Tests | 2013 |
Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study.
Topics: Allopurinol; Clinical Trials as Topic; Diabetic Nephropathies; Humans; Kidney; Kidney Function Tests | 2013 |
Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study.
Topics: Allopurinol; Clinical Trials as Topic; Diabetic Nephropathies; Humans; Kidney; Kidney Function Tests | 2013 |
Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
Topics: Animals; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ne | 2014 |
Early diabetic nephropathy in type 1 diabetes: new insights.
Topics: Angiotensin II Type 2 Receptor Blockers; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Disease | 2014 |
Uric acid as a biomarker and a therapeutic target in diabetes.
Topics: Biomarkers; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Nephropathies; Enzyme Inhibitors; H | 2015 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Between hyperfiltration and impairment: demystifying early renal functional changes in diabetic nephropathy.
Topics: Albuminuria; Cystatins; Cytokines; Diabetic Nephropathies; Glomerular Filtration Rate; Humans; Kidne | 2008 |
Serum uric acid as a new player in the development of diabetic nephropathy.
Topics: Allopurinol; Animals; Antimetabolites; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Disease Mo | 2011 |
Uric acid as a mediator of diabetic nephropathy.
Topics: Animals; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Humans; Uric Acid | 2011 |
Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Antioxidants; Clinical T | 2013 |
Uric acid and diabetes: Is there a link?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies | 2013 |
[Uric acid and diabetes mellitus].
Topics: Diabetes Mellitus; Diabetic Nephropathies; Gout; Humans; Uric Acid | 2004 |
[Management of hyperuricemia in diabetes].
Topics: Allopurinol; Benzbromarone; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; Human | 1997 |
Diuretics in nonedematous states. Physiological basis for the clinical use.
Topics: Acidosis, Renal Tubular; Barbiturates; Calcium; Chlorothiazide; Cystinuria; Diabetes Insipidus; Diab | 1973 |
[The kidney in gout and gout of the kidney].
Topics: Arteriosclerosis Obliterans; Carbohydrate Metabolism; Cerebrovascular Disorders; Diabetes Complicati | 1968 |
18 trials available for uric acid and Diabetic Nephropathies
| Article | Year |
|---|---|
Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies | 2020 |
Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia.
Topics: Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fenofibrate; Gl | 2020 |
Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.
Topics: Adult; Aged; Allopurinol; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; En | 2020 |
Effects of Allopurinol on the Progression of Chronic Kidney Disease.
Topics: Aged; Allopurinol; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Disease Progression; Double-Bl | 2020 |
Hyperuricemia and overexcretion of uric acid increase the risk of simple renal cysts in type 2 diabetes.
Topics: Aged; Cysts; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hyperuricemia; Kidne | 2017 |
The effect of uric acid lowering treatment on albuminuria and renal function in Type 1 diabetes: a randomized clinical trial.
Topics: Albuminuria; Allopurinol; Creatinine; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Nephro | 2018 |
Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).
Topics: Aged; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Hyper | 2018 |
High-Resistant Starch, Low-Protein Flour Intervention on Patients With Early Type 2 Diabetic Nephropathy: A Randomized Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Di | 2019 |
Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study).
Topics: Aged; Aged, 80 and over; Albuminuria; Amlodipine; Blood Pressure; Calcium Channel Blockers; Creatini | 2014 |
Can levothyroxine treatment reduce urinary albumin excretion rate in patients with early type 2 diabetic nephropathy and subclinical hypothyroidism? A randomized double-blind and placebo-controlled study.
Topics: Adult; Albumins; Autoantibodies; Cholesterol; Cholesterol, LDL; Diabetic Nephropathies; Double-Blind | 2015 |
Randomized control trial for the assessment of the anti-albuminuric effects of topiroxostat in hyperuricemic patients with diabetic nephropathy (the ETUDE study).
Topics: Diabetic Nephropathies; Glomerular Filtration Rate; Humans; Hyperuricemia; Nitriles; Pyridines; Trea | 2016 |
Metabolic basis for low urine pH in type 2 diabetes.
Topics: Adult; Age Factors; Aged; Biomarkers; Body Mass Index; Buffers; Diabetes Mellitus, Type 2; Diabetic | 2010 |
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathi | 2011 |
An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular System; Data Inter | 2012 |
Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy.
Topics: Aged; Blood Pressure; Blood Proteins; Blood Urea Nitrogen; Carbon; Cholesterol; Creatinine; Diabetic | 2004 |
Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis.
Topics: Adult; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disea | 2006 |
Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2007 |
Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Neph | 2000 |
128 other studies available for uric acid and Diabetic Nephropathies
| Article | Year |
|---|---|
Changes in serum uric acid levels as a predictor of future decline in renal function in older adults with type 2 diabetes.
Topics: Aged; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Gl | 2021 |
Association between uric acid level and incidence of albuminuria in patients with type 2 diabetes mellitus: A 4.5-year cohort study.
Topics: Aged; Albuminuria; Animals; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Femal | 2021 |
Clinical Predictors and Long-term Impact of Acute Kidney Injury on Progression of Diabetic Kidney Disease in Chinese Patients With Type 2 Diabetes.
Topics: Acute Kidney Injury; Aged; Asian People; China; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic | 2022 |
The association between glycaemic level and lipid profile with Albuminuria in Iraqi type 2 diabetes patients - A cross sectional study.
Topics: Adult; Aged; Albuminuria; Creatinine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic N | 2021 |
Antioxidation and Nrf2-mediated heme oxygenase-1 activation contribute to renal protective effects of hydralazine in diabetic nephropathy.
Topics: Allopurinol; Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucose | 2022 |
Sodium-glucose Cotransporter Type 2 Inhibitors: A New Insight into the Molecular Mechanisms of Diabetic Nephropathy.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Humans; Sodium; Sodium-Glucose Transport | 2022 |
Correlation of dehydroepiandrosterone with diabetic nephropathy and its clinical value in early detection.
Topics: Albumins; Albuminuria; Biomarkers; Cholesterol; Creatinine; Dehydroepiandrosterone; Diabetes Mellitu | 2022 |
Genomic DNA Methylation in Diabetic Chronic Complications in Patients With Type 2 Diabetes Mellitus.
Topics: Carotid Intima-Media Thickness; Cholesterol, LDL; Creatinine; Diabetes Mellitus, Type 2; Diabetic Ne | 2022 |
Value of Color Doppler Ultrasonography for Diagnosing Early Diabetic Nephropathy.
Topics: Albumins; Blood Glucose; Cystatin C; Diabetes Mellitus; Diabetic Nephropathies; Glycated Hemoglobin; | 2022 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Humans; | 2022 |
Elevated serum uric acid is not an independent risk factor for the occurrence of Type 2 diabetic kidney disease in Chinese populations.
Topics: Albuminuria; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; East Asian | 2022 |
Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Substitution; Febuxostat; Humans; Hyperurice | 2022 |
Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway.
Topics: Animals; Diabetic Nephropathies; Endothelial Cells; Febuxostat; Humans; Male; Mice; Mice, Inbred C57 | 2023 |
Association between brachial-ankle pulse wave velocity and microvascular complications in type 2 diabetes mellitus.
Topics: Ankle; Ankle Brachial Index; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diab | 2023 |
Is serum uric acid-to-HDL cholesterol ratio elevation associated with diabetic kidney injury?
Topics: Cholesterol, HDL; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney; Ret | 2023 |
Extracellular status of thrombospondin-2 in type 2 diabetes mellitus and utility as a biomarker in the determination of early diabetic kidney disease.
Topics: Animals; Biomarkers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Mice; Th | 2023 |
The correlation between serum uric acid and diabetic kidney disease in adult-onset type 1 diabetes patients in China.
Topics: Adult; China; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerul | 2023 |
Establishment of a potent weighted risk model for determining the progression of diabetic kidney disease.
Topics: Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Fibrinogen; Glycated Hemoglobin; | 2023 |
Serum Levels of Indoxyl Sulfate and P-cresol in Type II Diabetic Patients With and Without Nephropathy.
Topics: Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Indican; Proteinuria; Uric Ac | 2023 |
The Triglyceride Glucose (TyG) Index as a Sensible Marker for Identifying Insulin Resistance and Predicting Diabetic Kidney Disease.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Humans; Insul | 2023 |
The correlation between serum uric acid and diabetic kidney disease in type 1 diabetes patients in Anhui, China.
Topics: China; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Humans; Hyperuricemia; Uric Acid | 2023 |
Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice.
Topics: Animals; Anti-Inflammatory Agents; Body Weight; Chemokine CCL2; Collagen; Diabetic Nephropathies; Fe | 2019 |
Clinical Features and Microvascular Complications Risk Factors of Early-onset Type 2 Diabetes Mellitus.
Topics: Adult; Age of Onset; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Diabetes Mel | 2019 |
Is Uric Acid elevation a random finding or a causative agent of diabetic nephropathy?
Topics: Aged; Albuminuria; Biomarkers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female | 2019 |
Different associations between serum urate and diabetic complications in men and postmenopausal women.
Topics: Aged; Cross-Sectional Studies; Diabetes Complications; Diabetic Nephropathies; Female; Humans; Male; | 2020 |
Serum uric acid is independently associated with diabetic nephropathy but not diabetic retinopathy in patients with type 2 diabetes mellitus.
Topics: Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopat | 2020 |
Uric acid in diabetic nephropathy.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; | 2020 |
Comment on "Is Uric Acid elevation a random finding or a causative agent of diabetic nephropathy?"
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Uric Acid | 2020 |
Non-purine selective xanthine oxidase inhibitor ameliorates glomerular endothelial injury in Ins
Topics: Albuminuria; Ameloblasts; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease | 2020 |
Exogenous glutamine ameliorates diabetic nephropathy in a rat model of type 2 diabetes mellitus through its antioxidant and anti-inflammatory activities.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2023 |
Associations of serum uric acid level with diabetic retinopathy and albuminuria in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; F | 2020 |
Association between decreased thyroid stimulating hormone and hyperuricemia in type 2 diabetic patients with early-stage diabetic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; China; Diabetes Mellit | 2021 |
Malaysian Propolis and Metformin Synergistically Mitigate Kidney Oxidative Stress and Inflammation in Streptozotocin-Induced Diabetic Rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Creatinine; Diabetes Mellitus, Experimental; Diabet | 2021 |
Tubular injury in diabetic ketoacidosis: Results from the diabetic kidney alarm study.
Topics: Acute Kidney Injury; Adolescent; Biomarkers; Child; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis | 2021 |
Mendelian randomization to establish the causality of uric acid with diabetic nephropathy in type 1 diabetics.
Topics: Diabetes Mellitus, Type 1; Diabetic Nephropathies; Humans; Hyperuricemia; Random Allocation; Uric Ac | 2017 |
Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes.
Topics: Aged; Blood Glucose Self-Monitoring; Blood Pressure; Blood Pressure Determination; Databases, Factua | 2017 |
Increased Serum Uric Acid Level Is a Risk Factor for Left Ventricular Hypertrophy but Not Independent of eGFR in Patients with Type 2 Diabetic Kidney Disease.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; | 2017 |
The relationships among hyperuricemia, body mass index and impaired renal function in type 2 diabetic patients.
Topics: Adult; Aged; Body Mass Index; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2018 |
Serum 1,5-Anhydroglucitol Concentrations Remain Valid as a Glycemic Control Marker In Diabetes with Earlier Chronic Kidney Disease Stages.
Topics: Adult; Aged; Biomarkers; Deoxyglucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabeti | 2019 |
High fructose diet feeding accelerates diabetic nephropathy in Spontaneously Diabetic Torii (SDT) rats.
Topics: Animals; Diabetic Nephropathies; Dietary Carbohydrates; Disease Progression; Fructose; Glucose; Kidn | 2018 |
Correlations between blood uric acid and the incidence and progression of type 2 diabetes nephropathy.
Topics: Adult; Blood Urea Nitrogen; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephrop | 2018 |
Sex-related association of serum uric acid with inflammation, kidney function and blood pressure in type 1 diabetic patients.
Topics: Adolescent; Blood Pressure; Child; Cohort Studies; Diabetes Mellitus, Type 1; Diabetic Nephropathies | 2018 |
Analysis on influencing factors of abnormal renal function in elderly patients with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Albuminuria; Blood Glucose; Cholesterol; Creatinine; Diabetes Mellitus, Typ | 2020 |
Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes.
Topics: Biomarkers; Blood Pressure Determination; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes | 2019 |
Protective effects of sarsasapogenin against early stage of diabetic nephropathy in rats.
Topics: Anemarrhena; Animals; China; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drugs, Chinese | 2018 |
[Protective effects of Curcumin analogue L6H4 on kidney from type 2 diabetic rats].
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Collagen Type IV; Creatinine; Curcumin; Diabetes Mellit | 2017 |
[Related factors of diabetic nephropathy in patients with type 1 diabetes mellitus].
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2018 |
Interactive effect of serum uric acid and total bilirubin for micro-vascular disease of type 2 diabetes in China.
Topics: Aged; Bilirubin; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; D | 2018 |
Serum and urinary SOD3 in patients with type 2 diabetes: comparison with early chronic kidney disease patients and association with development of diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic N | 2019 |
Amelioration of diabetic nephropathy in db/db mice treated with tibetan medicine formula Siwei Jianghuang Decoction Powder extract.
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Creatinine; Curcuma; Diabetes Mellitus, Experimental; D | 2018 |
Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes.
Topics: Adult; Aged; Albuminuria; Biomarkers; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mel | 2019 |
Coexistence of hyper-uricaemia and low urinary uric acid excretion further increases risk of chronic kidney disease in type 2 diabetes.
Topics: Aged; Albuminuria; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Femal | 2019 |
Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An Observational Analysis From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Stu
Topics: Adolescent; Blood Pressure; Child; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephro | 2019 |
The association between serum uric acid to creatinine ratio and renal disease progression in type 2 diabetic patients in Chinese communities.
Topics: Adult; Aged; Case-Control Studies; China; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropath | 2019 |
Correlations of serum uric acid with glucose and lipid metabolism and renal function of type 2 diabetes mellitus patients.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; H | 2020 |
High Serum Uric Acid Is Associated with Tubular Damage and Kidney Inflammation in Patients with Type 2 Diabetes.
Topics: Aged; Biomarkers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Hepatitis A | 2019 |
Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular | 2019 |
Effect of silymarin on streptozotocin-nicotinamide-induced type 2 diabetic nephropathy in rats.
Topics: Albuminuria; Animals; Blood Glucose; Case-Control Studies; Creatinine; Diabetes Mellitus, Experiment | 2013 |
[Analyses on the relative factors regarding diabetic nephropathy].
Topics: Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Huma | 2013 |
Factors related with the progression of chronic kidney disease.
Topics: Aged; Anemia; Calcium; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Diabetic N | 2013 |
Serum uric acid, the metabolic syndrome, and the risk of chronic kidney disease in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephrop | 2014 |
High prevalence and risk factors for kidney dysfunction in patients with atherosclerotic cardio-cerebrovascular disease.
Topics: Age Factors; Aged; Aged, 80 and over; Atherosclerosis; Cerebrovascular Disorders; China; Coronary Di | 2014 |
[Risk stratification of diabetic chronic kidney disease using eGFR equations].
Topics: Blood Urea Nitrogen; Creatinine; Cystatin C; Diabetes Mellitus; Diabetic Nephropathies; Glomerular F | 2014 |
Association of serum uric acid with level of blood pressure in type 2 diabetic patients.
Topics: Aged; Biomarkers; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; | 2014 |
Low protein diet inhibits uric acid synthesis and attenuates renal damage in streptozotocin-induced diabetic rats.
Topics: Albuminuria; Animals; Cell Proliferation; Cell Size; Diabetes Mellitus, Experimental; Diabetic Nephr | 2014 |
Uric acid and risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention.
Topics: Aged; Biomarkers; Diabetic Nephropathies; Female; Humans; Hyperuricemia; Intraoperative Complication | 2014 |
Protective effect of bioflavonoid myricetin enhances carbohydrate metabolic enzymes and insulin signaling molecules in streptozotocin-cadmium induced diabetic nephrotoxic rats.
Topics: Albuminuria; Animals; Biomarkers; Blood Glucose; Blood Urea Nitrogen; Cadmium Chloride; Carbohydrate | 2014 |
Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats.
Topics: Animals; Blood Glucose; Cholesterol; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropat | 2014 |
Serum uric acid concentration is associated with early changes of glomerular filtration rate in patients with diabetes type 1 without increased albumin excretion.
Topics: Adult; Albuminuria; Biomarkers; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Early Diagnosis; | 2014 |
Metabonomics revealed xanthine oxidase-induced oxidative stress and inflammation in the pathogenesis of diabetic nephropathy.
Topics: Allantoin; Animals; Diabetic Nephropathies; Humans; Kidney; Magnetic Resonance Spectroscopy; Male; M | 2015 |
Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy.
Topics: Animals; Carrier Proteins; Cell Line; Chemokine CXCL12; Coculture Techniques; Diabetes Mellitus, Typ | 2015 |
Uric Acid is independently associated with diabetic kidney disease: a cross-sectional study in a Chinese population.
Topics: Biomarkers; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Femal | 2015 |
Relationship between serum uric acid levels and intrarenal hemodynamic parameters.
Topics: Adult; Aged; Algorithms; Blood Pressure; Diabetic Nephropathies; Female; Glomerular Filtration Rate; | 2015 |
Use of Contrast-Enhanced Ultrasound to Study Relationship between Serum Uric Acid and Renal Microvascular Perfusion in Diabetic Kidney Disease.
Topics: Contrast Media; Diabetic Nephropathies; Female; Humans; Kidney; Male; Middle Aged; Risk Factors; Ult | 2015 |
[Protective effect of astragalus saponin extracts on kidneys of diabetic rats].
Topics: Animals; Astragalus Plant; Blood Glucose; Blood Urea Nitrogen; Diabetic Nephropathies; Drugs, Chines | 2015 |
Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Albuminuria; Comorbidity; Cytokines; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 2015 |
Hyperfiltration and uricosuria in adolescents with type 1 diabetes.
Topics: Adolescent; Age Factors; Biomarkers; Case-Control Studies; Child; Creatinine; Cross-Sectional Studie | 2016 |
Serum uric acid predicts cardiovascular mortality in male peritoneal dialysis patients with diabetes.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Chi-Square Distribution; China; Di | 2016 |
Association of serum uric acid levels with the risk of development or progression of albuminuria among Japanese patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 10)].
Topics: Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; G | 2016 |
Association between serum uric acid related genetic loci and diabetic kidney disease in the Chinese type 2 diabetes patients.
Topics: Adaptor Proteins, Signal Transducing; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member | 2016 |
Effect of Cichorium intybus L. seed extract on renal parameters in experimentally induced early and late diabetes type 2 in rats.
Topics: Animals; Blood Glucose; Cichorium intybus; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nep | 2017 |
Serum uric acid and its association with hypertension, early nephropathy and chronic kidney disease in type 2 diabetic patients.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female | 2016 |
Serum uric acid to creatinine ratio: A predictor of incident chronic kidney disease in type 2 diabetes mellitus patients with preserved kidney function.
Topics: Aged; Biomarkers; Chi-Square Distribution; China; Creatinine; Diabetes Mellitus, Type 2; Diabetic Ne | 2017 |
The serum uric acid concentration is not causally linked to diabetic nephropathy in type 1 diabetes.
Topics: Adult; Albuminuria; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 1; Diabetic Nephrop | 2017 |
Correlations of six related purine metabolites and diabetic nephropathy in Chinese type 2 diabetic patients.
Topics: Adenosine; Aged; Asian People; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic | 2009 |
Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study.
Topics: Adolescent; Adult; Albuminuria; Blood Pressure; Cohort Studies; Diabetes Mellitus, Type 1; Diabetic | 2009 |
Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice.
Topics: Albuminuria; Allopurinol; Animals; Blood Pressure; Blood Urea Nitrogen; Cell Line; Diabetes Mellitus | 2009 |
Peroxynitrite mediates glomerular lesion of diabetic rat via JAK/STAT signaling pathway.
Topics: Animals; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibronectins; I | 2009 |
Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study.
Topics: Adult; Albuminuria; Biomarkers; Cohort Studies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; F | 2010 |
Inability of legumes to reverse diabetic-induced nephropathy in rats despite improvement in blood glucose and antioxidant status.
Topics: Animals; Antioxidants; Biomarkers; Blood Glucose; Blood Proteins; Diabetes Mellitus, Experimental; D | 2010 |
Beta-2 microglobulin levels in hemodialysis patients.
Topics: beta 2-Microglobulin; Creatinine; Cross-Sectional Studies; Diabetic Nephropathies; Female; Hematocri | 2010 |
Hyperuricemia and albuminuria in patients with type 2 diabetes mellitus.
Topics: Albuminuria; Blood Glucose; Creatinine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic | 2011 |
Factors associated with diabetic nephropathy in subjects with proliferative retinopathy.
Topics: Aged; Albuminuria; Blood Pressure; Blood Sedimentation; C-Reactive Protein; Circadian Rhythm; Diabet | 2012 |
Diabetes: Lowering serum uric acid levels to prevent kidney failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetic Nephropathies; Humans; Hyperuricemia; Kidney Failu | 2011 |
Risk profile in chronic kidney disease stage 3: older versus younger patients.
Topics: Age Factors; Aged; Aged, 80 and over; Albuminuria; Atherosclerosis; Cardiovascular Diseases; Diabeti | 2011 |
Serum uric acid is related to cardiovascular events and correlates with N-terminal pro-B-type natriuretic peptide and albuminuria in patients with diabetes mellitus.
Topics: Albuminuria; Atherosclerosis; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic | 2012 |
A study of the natural history of diabetic kidney disease (DKD).
Topics: Aged; Aged, 80 and over; Biomarkers; Blood Pressure; Cohort Studies; Diabetes Mellitus, Type 2; Diab | 2012 |
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of end points in noninsulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; | 2012 |
Effect of lovastatin therapy and withdrawal on serum uric acid level in people with type 2 diabetic nephropathy.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fasting; Female; Huma | 2012 |
[Uric acid, atherosclerosis and vascular calcifications in chronic kidney disease].
Topics: Adolescent; Adult; Aged; Atherosclerosis; Calcinosis; Cardiovascular Diseases; Chronic Disease; Como | 2012 |
Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation.
Topics: Acute Kidney Injury; Allopurinol; Analysis of Variance; Animals; Blood Urea Nitrogen; Blotting, West | 2012 |
Reducing serum uric acid attenuates TGF-β1-induced profibrogenic progression in type 2 diabetic nephropathy.
Topics: Animals; Biomarkers; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Mod | 2012 |
High prevalence of uric acid calculi in diabetic stone formers.
Topics: Diabetic Nephropathies; Female; France; Humans; Kidney Calculi; Male; Middle Aged; Prevalence; Retro | 2005 |
Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan.
Topics: Aged; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Lo | 2005 |
J-shaped mortality relationship for uric acid in CKD.
Topics: Adult; Aged; Allopurinol; Antimetabolites; Cause of Death; Comorbidity; Confounding Factors, Epidemi | 2006 |
Association of D-dimer with microalbuminuria in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Atherosclerosis; Biomarkers; Body Mass Index; Carotid A | 2009 |
High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes.
Topics: Adult; Age Factors; Albuminuria; Antihypertensive Agents; Blood Pressure; Cross-Sectional Studies; C | 2008 |
Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glycated Hemo | 2008 |
[Study of the course of development in 84 non-insulin-dependent diabetics over a 5-to-10-year period. Their therapeutic outcome].
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic | 1983 |
[The cardiovascular risk profile of long-term diabetics and its relation to kidney function].
Topics: Adolescent; Adult; Aged; Body Weight; Cholesterol; Coronary Disease; Creatinine; Diabetes Complicati | 1982 |
Association of elevated serum uric acid with coronary heart disease in diabetes mellitus.
Topics: Adolescent; Adult; Aged; Biomarkers; Body Weight; Coronary Disease; Cross-Sectional Studies; Diabete | 1993 |
[Kidney lesions in non-insulin dependent diabetes mellitus].
Topics: Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; G | 1995 |
Prevalence and risk factors for micro- and macroalbuminuria in an Italian population-based cohort of NIDDM subjects.
Topics: Aged; Albuminuria; Blood Glucose; Blood Pressure; Cohort Studies; Diabetes Mellitus, Type 2; Diabeti | 1996 |
Pattern of long-term complications in Sudanese insulin-treated diabetic patients.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Pressure; Cardiovascular Diseases; Cerebrovascular Disord | 1995 |
New prescription of peritoneal dialysis: intermittent ambulatory peritoneal dialysis.
Topics: Aged; Blood Urea Nitrogen; Creatinine; Diabetic Nephropathies; Electrolytes; Female; Humans; Kidney | 1996 |
[Renal hypouricemia in juvenile diabetes mellitus].
Topics: Adolescent; Blood Glucose; Child; Child, Preschool; Creatinine; Diabetes Mellitus, Type 1; Diabetic | 1996 |
Kidney function in phasic insulin dependent diabetes mellitus in Jamaica.
Topics: Albuminuria; Creatinine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathie | 1997 |
The association between the total antioxidant potential of plasma and the presence of coronary heart disease and renal dysfunction in patients with NIDDM.
Topics: Aged; Antioxidants; Ascorbic Acid; Biomarkers; Chromatography, High Pressure Liquid; Coronary Diseas | 1998 |
Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female | 2001 |
[Simultaneous determination of creatinine, pseudouridine and uric acid in serum and urine by high performance liquid chromatography].
Topics: Chromatography, High Pressure Liquid; Creatinine; Diabetic Nephropathies; Diabetic Retinopathy; Huma | 1998 |
Diabetic hypouricemia as an indicator of clinical nephropathy.
Topics: beta 2-Microglobulin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dietary Prot | 1990 |
Comparisons of peritoneal function between diabetic and nondiabetic patients with end stage renal disease.
Topics: Aged; Blood Urea Nitrogen; Creatinine; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Midd | 1990 |
Diabetic renal hypouricemia.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Tubules; Male; Midd | 1987 |
Short-term effect of 4% hypertonic glucose as compared to 4% mixed hypertonic mannitol solution in conventional peritoneal dialysis.
Topics: Adult; Aged; Blood Glucose; Blood Urea Nitrogen; Creatinine; Diabetic Nephropathies; Electrolytes; F | 1985 |
[Criteria for the selection and evaluation of diagnostic tests].
Topics: Blood Chemical Analysis; Clinical Laboratory Techniques; Creatinine; Diabetic Nephropathies; Glomeru | 1985 |
Management of renal disease in pregnancy.
Topics: Acute Disease; Anti-Infective Agents, Urinary; Bacteriuria; Chronic Disease; Diabetic Nephropathies; | 1972 |
Peritoneal dialysis with fructose dialysate. Prevention of hyperglycemia and hyperosmolality.
Topics: Blood; Diabetic Nephropathies; Fructose; Glucose; Humans; Hydrogen-Ion Concentration; Hyperglycemia; | 1973 |
[Severe metabolic acidosis in a diabetic during treatment with phenformin and allopurinol. A result of drug interaction?].
Topics: Acidosis; Aged; Allopurinol; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; Fema | 1970 |